Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: J Crit Care. 2015 Aug 1;30(6):1163–1168. doi: 10.1016/j.jcrc.2015.07.031

Table 1.

Baseline characteristics of the study cohort

Entire cohort (n=243) Serial Lactate Group (SL, n=132) No Serial Lactate Group (NL, n=111) p

Baseline characteristics

Age, yr 61.1 (16.7) 61.6 (15.8) 60.5 (17.8) 0.59

Female, n (%) 106 (43.6) 58 (44) 48 (43) 0.91

Race, n (%) 0.89
 - Caucasian 102 (42.0) 55 (42) 47 (42)
 - Other 141 (58.0) 77 (58) 64 (58)

Weight (kg) 77.1 (63.5–90.7) 77.9 (63.7–81.6) 77.1 (63.5–95.3) 0.44

Height (in) 67.0 (63.0–70.0) 67.0 (63.0–70.0) 66.0 (63.0–70.0) 0.65

PBW (kg) 62.6 (54.7–73.0) 61.6 (54.7–73.0) 62.6 (52.4–73.0) 0.65

BMI 26.1 (21.3–31.3) 25.7 (21.1–29.7) 27.2 (21.9–32.9) 0.11

Comorbidities, n (%)

 CHF 34 (14.0) 15 (11) 19 (17) 0.20

 Diabetes Mellitus 79 (32.5) 37 (28) 42 (38) 0.10

 COPD 37 (15.2) 12 (9) 25 (22) <0.01

 ESRD 18 (7.4) 8 (6) 10 (9) 0.38

 Liver Disease 32 (13.2) 17 (13) 15 (13) 0.88

 Malignancy 43 (17.7) 25 (19) 18 (16) 0.58

 Immunosuppression 24 (9.9) 13 (9.8) 11 (9.9) 0.99

 Alcohol 21 (8.6) 15 (11.4) 6 (5.4) 0.10

Temperature, C 36.7 (1.6) 36.7 (1.6) 36.7 (1.5) 1.0

SBP 83.2 (25.2) 81.5 (23.6) 85.2 (27.0) 0.26

HR 123.6 (24.5) 122.4 (24.5) 125.1 (24.5) 0.39

SpO2, (%) 95.0 (93.0–98.0) 95.0 (93.0–98.0) 94.0 (93.0–98.0) 0.39

WBC 14.2 (9.9–19.6) 14.0 (9.2–18.9) 14.5 (10.7–20.0) 0.24

Hemoglobin 11.5 (3.0) 11.6 (2.9) 11.5 (3.1) 0.92

Platelet 203.0 (137.0–301.0) 193.0 (125.0–296.0) 213.0 (146.0–302.0) 0.49

Bilirubin 0.7 (0.4–1.6) 0.8 (0.4–1.4) 0.6 (0.3–1.7) 0.85

Creatinine 1.3 (0.9–2.4) 1.4 (1.0–2.8) 1.3 (0.9–1.7) 0.09

INR 1.4 (1.2–1.7) 1.4 (1.2–1.7) 1.4 (1.1–1.7) 0.49

pH 7.28 (0.14) 7.28 (0.13) 7.28 (0.15) 0.73

Albumin 3.1 (0.8) 3.1 (0.8) 3.1 (0.7) 0.81

Lactate, (mmol/L) 5.7 (4.6–8.1) 5.8 (4.6–8.3) 5.6 (4.7–7.0) 0.51

SOFA* 4.0 (2.0–7.0) 4.0 (2.0–7.0) 4.0 (2.0–8.0) 0.79

Source of infection, n (%)

 Pulmonary 44 (18.1) 18 (13.6) 26 (23.4) 0.05

 Urinary 47 (19.3) 28 (21.2) 19 (17.1) 0.42

 Intra-abdominal 17 (7.0) 11 (8.3) 6 (5.4) 0.37

 Skin/soft tissue 13 (5.3) 5 (3.8) 8 (7.2) 0.24

 Blood 22 (9.0) 13 (9.8) 9 (8.1) 0.64

ED LOS (min) 407 (298.0–570.0) 458 (332.0–660.5) 359 (240.0–472.0) <0.01

Process-of-care variables

Time to antibiotics, min** 145.0 (91.0–247.0) 135.0 (87.0–258.5) 150.0 (100.0–243.0) 0.44

Intravenous crystalloid, L 3.1 (1.8) 3.6 (1.7) 2.5 (1.8) <0.01

Vasopressor use, n (%) 85 (34.5) 44 (33) 41 (37) 0.77

pRBC transfusion, n(%) 44(18.1) 24 (18) 20 (18) 0.97

Corticosteroids, n (%) 25 (10.3) 17 (13) 8 (7.4) 0.15

Mechanical ventilation, n (%) 97 (39.9) 42 (31.8) 55 (49.5) <0.01

Tidal volume, mL 500 (450–550) 500 (450–500) 500 (450–562.5) 0.10

Tidal volume, mL/kg PBW 7.9 (7.1–9.1) 7.7 (7.0–8.9) 8.4 (7.1–9.4) 0.14

Peak pressure, cmH2O (n=81) 25.0 (22.0–33.5) 25.0 (22.0–32.5) 26.5 (21.0–33.5) 0.80

Plateau pressure, cm H20 (n=74) 18.5 (16.0–24.0) 17.5 (15.0–22.5) 19.0 (16.0–24.0) 0.22

Continuous variables are reported as mean (standard deviation), and median (interquartile range). PBW: predicted body weight; BMI: body mass index; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; ESRD: end stage renal disease; SBP: systolic blood pressure; HR: heart rate; SpO2: peripheral oxygen saturation; WBC: white blood count; INR: international normalized ratio; SOFA: sequential organ failure assessment; ED: emergency department; LOS: length of stay, pRBC: packed red blood cell

*

Modified score, which excludes Glasgow Coma Score

**

All patients in the study received antimicrobial therapy.